Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
BLCM has three product candidates in clinical development: BPX-501, an adjunct T-cell therapy product candidate being evaluated in Phase I/II clinical trials in children and adults following a T-depleted, haploidentical hematopoietic stem cell transplant (HSCT); BPX-601, a GoCAR-T product candidate in Phase I development for solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate in Phase I development for AML with future development potential for treatment of solid tumors expressing the preferentially-expressed antigen in melanoma.
BLCM has collaboration agreements with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens.
Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
January 20, 2017
Higher open expected; RegMed Investors’ (RMi) pre-open, while everyone is watching the inauguration
January 19, 2017
RegMed Investors’ (RMi) closing bell analysis, value keeps slippin’ and sliding from the sector
January 19, 2017
Lower open expected; RegMed Investors’ (RMi) pre-open, the oversold are beckoning
January 18, 2017
RegMed Investors’ (RMi) closing bell analysis, short-term oversold conditions continue to challenge the sector
January 18, 2017
Higher open expected; RegMed Investors’ (RMi) pre-open, anticipating surprise
January 13, 2017
RegMed Investors’ (RMi) closing bell analysis, the week of hype was cut short
January 12, 2017
RegMed Investors’ (RMi) closing bell analysis, 2017 is starting off on a "fractured foot"
January 11, 2017
RegMed Investors’ (RMi) mid-day analysis, the sector gets a message nailed to the door …
January 10, 2017
RegMed Investors’ (RMi) closing bell analysis, some of the “dogs” of sector are getting sheared
January 9, 2017
RegMed Investors’ (RMi) closing bell analysis, the conference week that sets the tone of 2017 or does it?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Bellicum Pharmaceuticals (BCLM) - January '18 opened at $9.23, slipping to a low of $6.80 on 1/31 flowed by 2/1's $5.87 yet jumping to $6.60 by 2/16. After the KITE and JUNO acquisitions, many percieve that BLCM could be percieved as an appreciator in 2018 ... We do NEED to remember; the U.S. FDA placed a clinical hold on its lead product candidate BPX-501 that's being assessed as an adjunct T-cell therapy administered after haploidentical hematopoietic stem cell transplant. The hold reportedly stems from three cases of potentially treatment-related encephalopathy (abnormal brain function) that occurred during an ongoing trial. BLCM's shares were down 1/31/18 by 33.5% on heavy volume in response to this news.
buyMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.